Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche

HOFFMANN-LA ROCHE drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Drug Pipeline

HOFFMANN-LA ROCHE pipeline

Portfolio lens on 200 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

HOFFMANN-LA ROCHE drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

200 compounds

  1. 5-fu

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  2. abemaciclib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.

    Target
    Cyclin-dependent kinase 4
    Mechanism
    Cyclin-dependent kinase 6 inhibitor

  3. abiraterone

    Antineoplastic and immunomodulating agents (L02)

    Antineoplastic and immunomodulating agents (L02) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Steroid 5-alpha-reductase inhibitor

  4. abraxane

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  5. adagrasib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: GTPase KRas.

    Target
    GTPase KRas
    Mechanism
    GTPase KRas inhibitor

  6. administered

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  7. administration

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  8. aflibercept

    Sensory organs (S01)

    US regulatory status: approved. Molecular target: Placenta growth factor.

    Target
    Placenta growth factor
    Mechanism
    Placenta growth factor inhibitor

  9. alectinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: EML4-ALK.

    Mechanism
    EML4-ALK

  10. allopurinol

    Musculo-skeletal system (M04)

    US regulatory status: approved. Molecular target: Xanthine dehydrogenase/oxidase.

    Target
    Xanthine dehydrogenase/oxidase
    Mechanism
    Xanthine dehydrogenase inhibitor

  12. alzheimer

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  13. anti-

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  14. anti-melanoma mab fragments

    Various (V09)

    Various (V09) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  15. antibody

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  16. asenapine

    Nervous system (N05)

    US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.

    Mechanism
    Serotonin 2a (5-HT2a) receptor antagonist

  17. asenapine maleate

    US regulatory status: approved. Molecular target: D(2) dopamine receptor.

    Target
    D(2) dopamine receptor
    Mechanism
    Dopamine D2 receptor antagonist

  18. aspart

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  19. atezolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  20. atorvastatin

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.

    Mechanism
    HMG-CoA reductase inhibitor

  21. atra

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  22. atropine sulfate

    Sensory organs (S01)

    US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.

    Target
    Muscarinic acetylcholine receptor M1
    Mechanism
    Muscarinic acetylcholine receptor M3 antagonist

  24. axitinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.

    Target
    Vascular endothelial growth factor receptor
    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  25. baloxavir

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Molecular target: Polymerase acidic protein.

    Target
    Polymerase acidic protein
    Mechanism
    Polymerase acidic protein inhibitor

  26. baloxavir marboxil

    US regulatory status: approved. Molecular target: Polymerase acidic protein.

    Target
    Polymerase acidic protein
    Mechanism
    Polymerase acidic protein inhibitor

  27. barium sulfate

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  28. bendamustine

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  29. bevacizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  30. biological

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  31. budesonide

    Alimentary tract and metabolism (A07)

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  32. calcitriol

    US regulatory status: approved. Molecular target: Vitamin D3 receptor.

    Target
    Vitamin D3 receptor
    Mechanism
    Vitamin D receptor agonist

  33. capecitabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  34. capsule

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  35. capsules

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  36. carboplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  37. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  38. cells

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  39. cend-

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  40. cetuximab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  41. chemotherapy

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  42. chlorambucil

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  43. chloride

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  44. cisplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  45. cobimetinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.

    Target
    Dual specificity mitogen-activated protein kinase kinase 1
    Mechanism
    Dual specificity mitogen-activated protein kinase kinase 2 inhibitor

  46. combination

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  48. control

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  49. crizotinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.

    Target
    ALK tyrosine kinase receptor
    Mechanism
    Hepatocyte growth factor receptor inhibitor

  50. crovalimab

    Antineoplastic and immunomodulating agents (L04)

    Antineoplastic and immunomodulating agents (L04) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Complement C5.

    Target
    Complement C5
    Mechanism
    Complement C5 inhibitor

  51. cyclophosphamide

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  52. cytarabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  53. delandistrogene moxeparvovec

    Musculo-skeletal system (M09)

    Musculo-skeletal system (M09) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Dystrophin.

    Target
    Dystrophin
    Mechanism
    Dystrophin exogenous gene

  54. dengue tetravalent vaccine (live, attenuated)

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: Biological vaccine - induces immune response.

    Mechanism
    Biological vaccine - induces immune response

  55. dexamethasone sodium phosphate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  56. diphenhydramine

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.

    Mechanism
    Histamine H1 receptor antagonist

  57. diphenhydramine hydrochloride

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  58. docetaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  59. dornase alfa

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA hydrolytic enzyme

  60. dose

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  61. doxorubicin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  62. durvalumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  63. eculizumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Complement C5.

    Target
    Complement C5
    Mechanism
    Complement C5 inhibitor

  64. efmoroctocog alfa

    Blood and blood forming organs (B02)

    Blood and blood forming organs (B02) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Coagulation factor VIII.

    Target
    Coagulation factor VIII
    Mechanism
    Coagulation factor VIII exogenous protein

  65. emicizumab

    Blood and blood forming organs (B02)

    US regulatory status: approved. Molecular target: Coagulation factor IX and X.

    Target
    Coagulation factor IX and X
    Mechanism
    Coagulation factor IX and X other

  66. empagliflozin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.

    Target
    Sodium/glucose cotransporter 2
    Mechanism
    Sodium/glucose cotransporter 2 inhibitor

  67. endocrine

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  68. entecavir

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: DNA polymerase/reverse transcriptase.

    Target
    DNA polymerase/reverse transcriptase
    Mechanism
    DNA polymerase/reverse transcriptase inhibitor

  69. entrectinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.

    Target
    ALK tyrosine kinase receptor
    Mechanism
    Neurotrophic tyrosine kinase receptor inhibitor

  70. enzalutamide

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  71. epithelial

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  72. epoetin alfa-epbx

    US regulatory status: approved. Molecular target: Erythropoietin receptor.

    Target
    Erythropoietin receptor
    Mechanism
    Erythropoietin receptor agonist

  73. epoetin beta

    Blood and blood forming organs (B03)

    Blood and blood forming organs (B03) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Erythropoietin receptor.

    Target
    Erythropoietin receptor
    Mechanism
    Erythropoietin receptor agonist

  74. eptacog alfa (activated)

    Blood and blood forming organs (B02)

    Blood and blood forming organs (B02) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Coagulation factor VII.

    Target
    Coagulation factor VII
    Mechanism
    Coagulation factor VII exogenous protein

  75. erlotinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: Epidermal growth factor receptor erbB1 inhibitor.

    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  76. erlotinib hydrochloride

    US regulatory status: approved. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  77. estropipate

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  78. etoposide

    US regulatory status: approved. Molecular target: DNA topoisomerase II.

    Target
    DNA topoisomerase II
    Mechanism
    DNA topoisomerase II inhibitor

  79. expansion

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  80. faricimab

    Sensory organs (S01)

    Sensory organs (S01) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Angiopoietin-2.

    Target
    Angiopoietin-2
    Mechanism
    Angiopoietin-2 inhibitor

  81. filgrastim

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.

    Target
    Granulocyte colony-stimulating factor receptor
    Mechanism
    Granulocyte colony stimulating factor receptor agonist

  82. fingolimod

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Mechanism: Sphingosine 1-phosphate receptor binding agent.

    Mechanism
    Sphingosine 1-phosphate receptor binding agent

  83. fingolimod hydrochloride

    US regulatory status: approved. Molecular target: Sphingosine 1-phosphate receptor.

    Target
    Sphingosine 1-phosphate receptor
    Mechanism
    Sphingosine 1-phosphate receptor agonist

  84. florbetaben (18f)

    Various (V09)

    Various (V09) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  85. florbetaben f-18

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  86. florbetapir f-18

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  87. fluconazole

    US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.

    Target
    Lanosterol 14-alpha demethylase
    Mechanism
    Cytochrome P450 51 inhibitor

  88. fludarabine phosphate

    US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).

    Target
    DNA polymerase (alpha/delta/epsilon)
    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  89. fluorouracil

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  90. flutemetamol (18f)

    Various (V09)

    Various (V09) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  91. flutemetamol f-18

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  92. formulation

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  93. fulvestrant

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor antagonist

  94. ganciclovir

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.

    Target
    DNA polymerase catalytic subunit
    Mechanism
    Human herpesvirus 1 DNA polymerase inhibitor

  95. gemcitabine

    US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.

    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  96. glofitamab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  97. glofitamab-gxbm

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  98. group

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  99. hema-

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  100. hexocyclium methylsulfate

    US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.

    Target
    Muscarinic acetylcholine receptor M1
    Mechanism
    Muscarinic acetylcholine receptor M1 antagonist

  102. hydromorphone

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Mechanism: Mu opioid receptor agonist.

    Mechanism
    Mu opioid receptor agonist

  103. ibandronate

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  104. ibandronate sodium

    US regulatory status: approved. Molecular target: Farnesyl pyrophosphate synthase.

    Target
    Farnesyl pyrophosphate synthase
    Mechanism
    Farnesyl diphosphate synthase inhibitor

  105. ibandronic acid

    Musculo-skeletal system (M05)

    Musculo-skeletal system (M05) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: Farnesyl diphosphate synthase inhibitor.

    Mechanism
    Farnesyl diphosphate synthase inhibitor

  106. ifosfamide

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  107. inactivated

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  108. inavolisib

    US regulatory status: approved. Molecular target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform.

    Target
    Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
    Mechanism
    PI3-kinase p110-alpha subunit inhibitor

  111. infusion

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  112. inhibitor

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  113. inhibitors

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  114. injection

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  115. insulin

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  116. interferon alfa-2a

    Antineoplastic and immunomodulating agents (L03)

    Antineoplastic and immunomodulating agents (L03) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Interferon alpha/beta receptor.

    Target
    Interferon alpha/beta receptor
    Mechanism
    Interferon alpha/beta receptor agonist

  117. intravenous

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  118. itraconazole

    US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.

    Target
    Lanosterol 14-alpha demethylase
    Mechanism
    Cytochrome P450 51 inhibitor

  119. ketorolac tromethamine

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  120. lebrikizumab

    Dermatologicals (D11)

    Dermatologicals (D11) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Interleukin-13.

    Target
    Interleukin-13
    Mechanism
    Interleukin-13 inhibitor

  121. lenalidomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.

    Target
    CRL4(CRBN) E3 ubiquitin ligase
    Mechanism
    CRL4(CRBN) E3 ubiquitin ligase inhibitor

  122. letrozole

    US regulatory status: approved. Molecular target: Aromatase.

    Target
    Aromatase
    Mechanism
    Cytochrome P450 19A1 inhibitor

  123. leuprorelin

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  125. levodopa + carbidopa

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  126. linagliptin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Dipeptidyl peptidase 4.

    Target
    Dipeptidyl peptidase 4
    Mechanism
    Dipeptidyl peptidase IV inhibitor

  127. lurbinectedin

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA negative modulator

  128. malathion

    US regulatory status: approved. Molecular target: Acetylcholinesterase.

    Target
    Acetylcholinesterase
    Mechanism
    Acetylcholinesterase inhibitor

  129. malignant

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  130. management

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  131. medication

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  132. methoxy polyethylene glycol-epoetin beta

    Blood and blood forming organs (B03)

    US regulatory status: approved. Molecular target: Erythropoietin receptor.

    Target
    Erythropoietin receptor
    Mechanism
    Erythropoietin receptor agonist

  133. methylprednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  134. methylprednisolone acetate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  135. methylprednisolone sodium succinate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  136. midazolam

    Nervous system (N05)

    US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    GABA-A receptor; anion channel positive allosteric modulator

  137. monoclonal

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  138. monotherapy

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  139. mosunetuzumab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  140. mycophenolate

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Molecular target: Inosine-5'-monophosphate dehydrogenase (IMPDH).

    Target
    Inosine-5'-monophosphate dehydrogenase (IMPDH)
    Mechanism
    Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor

  141. mycophenolate mofetil

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Inosine-5'-monophosphate dehydrogenase (IMPDH).

    Target
    Inosine-5'-monophosphate dehydrogenase (IMPDH)
    Mechanism
    Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor

  142. nitrazepam

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  143. nivolumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  144. obinutuzumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  145. ocrelizumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  146. octocog alfa

    Blood and blood forming organs (B02)

    Blood and blood forming organs (B02) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Coagulation factor VIII.

    Target
    Coagulation factor VIII
    Mechanism
    Coagulation factor VIII exogenous protein

  147. olaparib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: PARP 1, 2 and 3.

    Target
    PARP 1, 2 and 3
    Mechanism
    PARP 1, 2 and 3 inhibitor

  148. omid

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  149. oxaliplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  150. paclitaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  151. palbociclib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: CDK6/cyclin D1.

    Target
    CDK6/cyclin D1
    Mechanism
    Cyclin-dependent kinase 4/cyclin D1 inhibitor

  152. paracetamol

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.

    Target
    Fatty-acid amide hydrolase 1
    Mechanism
    Anandamide amidohydrolase inhibitor

  153. pd-

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  154. pegfilgrastim

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.

    Target
    Granulocyte colony-stimulating factor receptor
    Mechanism
    Granulocyte colony stimulating factor receptor agonist

  155. peginterferon

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  156. peginterferon alfa-2a

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.

    Target
    Interferon alpha/beta receptor
    Mechanism
    Interferon alpha/beta receptor agonist

  157. pembrolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  158. pemetrexed

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  159. pemetrexed disodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  160. pemetrexed sodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  161. pertuzumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Receptor protein-tyrosine kinase erbB-2 inhibitor

  162. pioglitazone

    Alimentary tract and metabolism (A10)

    Alimentary tract and metabolism (A10) compound in HOFFMANN-LA ROCHE's portfolio. Mechanism: Peroxisome proliferator-activated receptor gamma agonist.

    Mechanism
    Peroxisome proliferator-activated receptor gamma agonist

  163. pioglitazone hydrochloride

    US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor gamma.

    Target
    Peroxisome proliferator-activated receptor gamma
    Mechanism
    Peroxisome proliferator-activated receptor gamma agonist

  164. pirtobrutinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  165. placebo

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  166. polatuzumab

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  167. polatuzumab vedotin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: B-cell antigen receptor complex-associated protein beta chain.

    Target
    B-cell antigen receptor complex-associated protein beta chain
    Mechanism
    B-cell antigen receptor complex-associated protein beta chain binding agent

  168. polyethylene

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  169. potassium chloride

    US regulatory status: approved. Mechanism: Supplement.

    Mechanism
    Supplement

  170. powder

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  171. prednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  172. prednisone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  173. pretreatment

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  174. protocol

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  175. ranibizumab

    Sensory organs (S01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  176. rasburicase

    Various (V03)

    US regulatory status: approved. Molecular target: Uric acid.

    Target
    Uric acid
    Mechanism
    Uric acid oxidative enzyme

  177. ribavirin

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: Inosine-5'-monophosphate dehydrogenase 1.

    Target
    Inosine-5'-monophosphate dehydrogenase 1
    Mechanism
    Inosine-5'-monophosphate dehydrogenase 1 inhibitor

  178. ribociclib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.

    Target
    Cyclin-dependent kinase 4
    Mechanism
    Cyclin-dependent kinase 6 inhibitor

  179. ribociclib succinate

    US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.

    Target
    Cyclin-dependent kinase 4
    Mechanism
    Cyclin-dependent kinase 4 inhibitor

  180. risdiplam

    Musculo-skeletal system (M09)

    US regulatory status: approved. Molecular target: SMN2 pre-mRNA.

    Target
    SMN2 pre-mRNA
    Mechanism
    SMN2 pre-mRNA positive modulator

  181. rituximab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  182. sacituzumab

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  183. sacituzumab govitecan

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I inhibitor

  184. satralizumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: IL6Ralpha/GP130.

    Target
    IL6Ralpha/GP130
    Mechanism
    IL6Ralpha/GP130 antagonist

  185. semaglutide

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.

    Target
    Glucagon-like peptide 1 receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist

  187. solution

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  188. solvent

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  189. sotorasib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: GTPase KRas.

    Target
    GTPase KRas
    Mechanism
    GTPase KRas inhibitor

  190. statin

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  191. stro-

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  192. subcutaneous

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  193. sunitinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in HOFFMANN-LA ROCHE's portfolio. Molecular target: Macrophage colony-stimulating factor 1 receptor.

    Target
    Macrophage colony-stimulating factor 1 receptor
    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  194. suspension

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  195. tablet

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  196. tablets

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  197. tacrolimus

    Dermatologicals (D11)

    US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.

    Target
    Peptidyl-prolyl cis-trans isomerase FKBP1A
    Mechanism
    FK506-binding protein 1A inhibitor

  198. targeted

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  199. taxane

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

  200. therapy

    Development asset linked to HOFFMANN-LA ROCHE in public FDA and regional records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.